US FDA and State Regulators Tighten Oversight of Compounded GLP‑1 Peptides

State health agencies are adding stricter enforcement requirements to the federal baseline for compounding GLP‑1 receptor agonists such as semaglutide and tirzepatide. While the FDA has relaxed rules on many peptides, it is moving in the opposite direction for GLP‑1 drugs, and the Pharmacy Compounding Advisory Committee is slated to review their status.

A parallel public‑health warning highlights the dangers of DIY peptide injections sold on the gray market. Products are unregulated, may contain contaminants, and users often make serious administration errors. A recent study of volunteers injecting semaglutide showed frequent mistakes, and a peptide company CEO was sentenced to 70 months in prison for distributing substandard products.